Clinical progress of KRAS-targeted therapies: what next?-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Clinical progress of KRAS-targeted therapies: what next?

Published:2022-08 Issue:15 Volume:14 Page:1107-1110
ISSN:1756-8919
Container-title:Future Medicinal Chemistry
language:en
Short-container-title:Future Medicinal Chemistry

Author:

Nagasaka Misako¹²^ORCID,Azmi Asfar S³^ORCID

Affiliation:

1. University of California Irvine School of Medicine, Chao Family Comprehensive Cancer Center, Orange, CA 92868, USA

2. Department of Internal Medicine, Division of Neurology, St. Marianna University, Kawasaki, Japan

3. Department of Oncology, Wayne State University School of Medicine, Detroit, MI 48201, USA

Funder

National Cancer Institute

Publisher

Future Science Ltd

Subject

Drug Discovery,Pharmacology,Molecular Medicine

Link

https://www.future-science.com/doi/pdf/10.4155/fmc-2022-0128

Reference16 articles.

1. RAS oncogenes: the first 30 years

2. Small-molecule modulation of Ras signaling

3. Targeting the MAPK Pathway in KRAS-Driven Tumors

4. A brief history of RAS and the RAS Initiative

5. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery of a Potent Dual Son of Sevenless 1 (SOS1) and Epidermal Growth Factor Receptor (EGFR) Inhibitor for the Treatment of Prostate Cancer;Journal of Medicinal Chemistry;2024-04-17

2. Quantitative Membrane Proteomics for Discovery of Actionable Drug Targets at the Surface of RAS-Driven Human Cancer Cells;Methods in Molecular Biology;2024

3. Detection and Quantitation of Endogenous Membrane-Bound RAS Proteins and KRAS Mutants in Cancer Cell Lines Using 1D-SDS-PAGE LC–MS2;Methods in Molecular Biology;2024

4. The Path to Personalized Treatment in KRAS-Mutant Non-Small Cell Lung Cancer: A Review of Targeted Therapies and Immunotherapy;Cancer Management and Research;2022-12

5. A Long Overdue Targeted Treatment for KRAS Mutations in NSCLC: Spotlight on Adagrasib;Lung Cancer: Targets and Therapy;2022-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3